Oncology blog posts

20 August, 2018

5 reasons why the R2G2® mouse could help you achieve your oncology research milestones

By Jamie Naden

The R2G2® mouse has the potential to help you break new ground in investigational cancer therapies. In two recent studies, this model tolerated standard of care chemotherapy and estrogen supplementation well in terms of overall survival and changes in body weight. Here are five reasons why this mouse model could serve as an excellent host for your preclinical human tumor xenograft studies.

+ Read more
 

30 May, 2018

Joining forces to drive breakthroughs in the treatment of cancer

By Freddie Campbell

Cancer continues to be one of the main areas of focus in drug development. Unmet patient needs and advances in the understanding of cancer biology is resulting in exciting development in cancer treatments. We recently partnered with the National Foundation for Cancer Research at the American Association for Cancer Research (AACR) Annual Meeting where we explored groundbreaking advancements in cancer research and helped attendees recognize the power of their donations to build a healthier and safer world.

+ Read more
 

22 November, 2017

Best practices for bridging studies to generate data and validate a new strain

By Travis Rothrock

In this final blog on bridging studies, we provide general best-practices relevant to oncology bridging studies, including basic study design considerations and insights that are the culmination of many years of hands-on experience by Envigo experts.

+ Read more
 

22 November, 2017

The importance of bridging studies when switching strains

By Travis Rothrock

Bridging studies play an important role in drug development, both in the clinical and preclinical stages. These studies provide important information that can circumvent the repetition of entire programs. Understanding the considerations and steps in switching rodent strains and the importance of bridging studies, is critical. In this post we outline the best practices on bridging studies.

+ Read more
 

22 November, 2017

Bridging studies - Why do researchers switch rodent strains?

By Travis Rothrock

Selecting the right model and rodent strain for your oncology studies can maximize the chances of success. However, there is an ever-increasing portfolio of available models and strains that may perform better than existing ones and may be more optimal for specific study purposes.

Increasing investigators are seeking to bridge from an existing rodent strain to another for their oncology preclinical efficacy and pharmacology studies. The short-term barriers associated with switching strains can appear complex and daunting, but another strain may actually be the key to the success of your oncology preclinical program.

Be sure to understand how you can benefit from switching to a new oncology rodent strain.

+ Read more
 

04 August, 2017

The two habits of highly effective CRO interactions

By Scott Wadsworth, PhD, PMP

Follow these two habits and you'll have discovered the secret to maximizing the effectiveness of your early interactions with a non-clinical CRO.

+ Read more
 

19 April, 2017

How to select the right oncology model

By Travis Rothrock

Key considerations for selecting the most appropriate oncology model
Today’s breakthrough oncology treatments are the result of years of research and testing. Animal models represent an essential part of this ongoing effort to improve human health and better understand a treatment’s potential in humans. That’s why the specific model selected for testing can mean the difference between success and failure in a study.

Here we discuss the factors to consider when selecting the right animal model for your oncology research

+ Read more